Clin2
NCT06931080Possibly a fitRecruiting

Study of EB-1020 for adults with ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

Treatments studied

Part of Mental health clinical trials.

This trial tests a new medication called EB-1020 for adults with ADHD. It aims to see if the drug is safe and effective in improving ADHD symptoms. You may be able to join if you have a clear ADHD diagnosis and your symptoms are moderate to severe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
630 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You must be an adult with a confirmed diagnosis of ADHD, based on a detailed interview.
  • Your ADHD symptoms must be significant: if you're not on ADHD medication, a score of 28 or higher on a symptom scale; if you are on medication, a score of 22 or higher.
  • You cannot be pregnant or breastfeeding.
  • You must not have another serious mental health condition like bipolar disorder, schizophrenia, severe anxiety, depression, or a personality disorder.
  • You cannot have a history of seizures, certain heart conditions, or other serious medical problems.
  • You must be willing to stop taking your current ADHD medication or other prohibited drugs for the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06926829Recruiting· Phase 3
Long-term study of EB-1020 for adults with ADHD

This trial is for adults with ADHD who completed a previous study of the drug EB-1020. It tests the long-term safety and effectiveness of the medication over an extended period.

Tokyo
NCT07086313Recruiting· Phase 2/Phase 3
Testing a new ADHD drug for children

This trial tests an experimental drug (EB-1020) for children with ADHD. It aims to see if the drug is safe and effective in reducing ADHD symptoms.

Sapporo
NCT07087327Recruiting· Phase 3
Long-term study of EB-1020 for children with ADHD

This trial tests a new medication, EB-1020, over a longer period in children with ADHD. It aims to see if the drug continues to be safe and effective beyond the initial 6-week treatment. Some participants may have already been in a previous EB-1020 study, while others are new.

Sapporo
NCT07300956Not yet recruiting· Phase 4
ADHD medication study for young children

This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.

Palo Alto, California
NCT06967857Recruiting· Phase 2
Dexamfetamine for adults with ADHD and depression

This trial tests a study medication (dexamfetamine) for adults who have both ADHD and moderate to severe depression. It aims to see if the medication is safe and helps improve both conditions.

Frankfurt
NCT06853665Recruiting· Phase 4
Study of mixed amphetamine for autism and ADHD in teens

This trial tests if a mixed amphetamine medication helps teenagers with both autism and ADHD who still have significant symptoms, even if they are already on other treatments. It also includes typically developing teens as a comparison group.

Boston, Massachusetts

Hear when a new Attention Deficit Hyperactivity Disorder (ADHD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.